[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-001", "question": "A 56-year-old man with long-standing type 2 diabetes, CKD stage 3b, and prior NSTEMI presents for routine follow-up. Medications: metformin 500 mg BID, empagliflozin 10 mg daily, lisinopril 20 mg daily, metoprolol succinate 100 mg daily, and high-intensity statin. BP is 118/66 mm Hg, BMI 31 kg/m², A1c 7.2%. eGFR is 37 mL/min/1.73 m², urinary ACR 620 mg/g (persistent over 9 months), potassium 4.6 mEq/L. He has no hyperkalemia history. Which change in therapy is most appropriate to further reduce his cardiorenal risk?", "options": ["Increase empagliflozin to 25 mg daily", "Add finerenone with close potassium monitoring", "Replace lisinopril with sacubitril/valsartan", "Add basal insulin to target A1c <6.5%", "Add a non-dihydropyridine calcium channel blocker"], "answer": "B", "answer_index": 1, "explanation": "Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces CV events and CKD progression in diabetics with albuminuric CKD already on ACEi/ARB and SGLT2i and with eGFR >25 and K<4.8. Increasing SGLT2 dose adds minimal incremental renal protection, sacubitril/valsartan is not indicated without HFrEF, tighter glycemic control adds little cardiorenal benefit with more risk, and non-DHP CCBs do not provide proven outcome benefit here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-standing T2DM; CKD stage 3b with eGFR 37; persistent severe albuminuria (ACR 620 mg/g for 9 months); prior NSTEMI (high CV risk); currently on ACE inhibitor (lisinopril), SGLT2 inhibitor (empagliflozin 10 mg), good BP control, reasonable A1c 7.2%; potassium 4.6 mEq/L; no history of hyperkalemia. These match the evidence-based indication for finerenone (nonsteroidal MRA) to further reduce cardiorenal risk on top of ACEi/ARB and SGLT2i when eGFR >25 and K <4.8.\\nOption analysis: A) Higher empagliflozin dose offers minimal incremental renal benefit; trials used fixed standard doses. B) Matches FIDELIO-DKD/FIGARO-DKD criteria; strongest proven additional risk reduction. C) Sacubitril/valsartan is indicated for HFrEF; no HF history provided. D) Tightening A1c to <6.5% in older patient with ASCVD/CKD adds risk (hypoglycemia) with little additional cardiorenal benefit. E) Non-DHP CCBs help proteinuria but lack robust outcome data vs finerenone and BP already optimal.\\nMain medical issues: None significant; teaching point aligns with current KDIGO/ADA/ACC guidance.\\nMinimal fix: Explicitly note “no history of heart failure” to preempt any misinterpretation of sacubitril/valsartan indication.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-standing T2DM; CKD stage 3b with eGFR 37; persistent severe albuminuria (ACR 620 mg/g for 9 months); prior NSTEMI (high CV risk); currently on ACE inhibitor (lisinopril), SGLT2 inhibitor (empagliflozin 10 mg), good BP control, reasonable A1c 7.2%; potassium 4.6 mEq/L; no history of hyperkalemia. These match the evidence-based indication for finerenone (nonsteroidal MRA) to further reduce cardiorenal risk on top of ACEi/ARB and SGLT2i when eGFR >25 and K <4.8.\nOption analysis: A) Higher empagliflozin dose offers minimal incremental renal benefit; trials used fixed standard doses. B) Matches FIDELIO-DKD/FIGARO-DKD criteria; strongest proven additional risk reduction. C) Sacubitril/valsartan is indicated for HFrEF; no HF history provided. D) Tightening A1c to <6.5% in older patient with ASCVD/CKD adds risk (hypoglycemia) with little additional cardiorenal benefit. E) Non-DHP CCBs help proteinuria but lack robust outcome data vs finerenone and BP already optimal.\nMain medical issues: None significant; teaching point aligns with current KDIGO/ADA/ACC guidance.\nMinimal fix: Explicitly note “no history of heart failure” to preempt any misinterpretation of sacubitril/valsartan indication.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-002", "question": "A 4-year-old boy is brought to the ED with 2 days of fever, abdominal pain, and vomiting. PMH includes Kawasaki disease at 11 months treated with IVIG and aspirin; echocardiography then showed a 7-mm giant aneurysm of the left anterior descending coronary artery, which has since regressed to normal dimensions by age 3. He is off antiplatelets and asymptomatic at baseline. Current vitals: T 39.2°C, HR 145/min, BP 82/48 mm Hg, RR 30/min, SpO2 95% RA. He appears ill and mottled with cool extremities. ECG shows sinus tachycardia with ST-segment depression in V4-V6. High-sensitivity troponin is mildly elevated. Bedside echo shows mild global LV dysfunction (EF 45%), no visible aneurysm. After fluid resuscitation and initiation of broad-spectrum antibiotics, which management step is most appropriate now?", "options": ["Re-treat with high-dose IVIG and start high-dose aspirin", "Obtain emergent coronary CT angiography and start IV heparin", "Start IV milrinone and low-dose aspirin without additional imaging", "Start IV methylprednisolone plus IVIG and transfer for ECMO standby", "Begin norepinephrine for septic shock and defer cardiac-specific therapy"], "answer": "B", "answer_index": 1, "explanation": "Children with prior giant Kawasaki aneurysms remain at risk for thrombosis and stenosis despite angiographic regression; acute coronary syndrome can mimic sepsis. ST depression, hypotension, and troponin elevation warrant urgent coronary imaging (CT angiography) and antithrombotic therapy. Routine retreatment with IVIG is not indicated years later, steroids/ECMO are premature without refractory shock, and treating as isolated sepsis risks missing coronary occlusion.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Prior giant (7-mm) LAD aneurysm from Kawasaki disease, now angiographically regressed; currently febrile and hypotensive but with mottled, cool extremities, sinus tachycardia plus ST-segment depression in V4–V6, mildly elevated troponin, and reduced EF (45%) despite initial sepsis management. These features point to possible acute coronary syndrome/ischemia or thrombosis in a high‑risk coronary artery, not just simple septic shock.\\nOption B is best because emergent coronary CT angiography is an appropriate, rapid, noninvasive method to evaluate for coronary thrombosis/stenosis in such a child, and IV heparin is indicated for suspected coronary thrombosis/ACS in patients with prior giant aneurysms. A (repeat IVIG/high‑dose ASA) is inappropriate years after the acute KD phase without evidence of new vasculitis. C ignores the need to rule out mechanical coronary lesions and omits full antithrombotic therapy. D (IVIG/steroids/ECMO standby) mis-targets the pathophysiology (late ACS vs acute KD) and is excessive. E (treat as pure septic shock) risks missing ACS.\\nMedical content is current and consistent with pediatric KD and coronary sequelae literature.\\nMinimal fix: Briefly state that sepsis workup is ongoing but cultures/imaging have not yet revealed a source, clarifying the diagnostic uncertainty prompting coronary imaging.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Prior giant (7-mm) LAD aneurysm from Kawasaki disease, now angiographically regressed; currently febrile and hypotensive but with mottled, cool extremities, sinus tachycardia plus ST-segment depression in V4–V6, mildly elevated troponin, and reduced EF (45%) despite initial sepsis management. These features point to possible acute coronary syndrome/ischemia or thrombosis in a high‑risk coronary artery, not just simple septic shock.\nOption B is best because emergent coronary CT angiography is an appropriate, rapid, noninvasive method to evaluate for coronary thrombosis/stenosis in such a child, and IV heparin is indicated for suspected coronary thrombosis/ACS in patients with prior giant aneurysms. A (repeat IVIG/high‑dose ASA) is inappropriate years after the acute KD phase without evidence of new vasculitis. C ignores the need to rule out mechanical coronary lesions and omits full antithrombotic therapy. D (IVIG/steroids/ECMO standby) mis-targets the pathophysiology (late ACS vs acute KD) and is excessive. E (treat as pure septic shock) risks missing ACS.\nMedical content is current and consistent with pediatric KD and coronary sequelae literature.\nMinimal fix: Briefly state that sepsis workup is ongoing but cultures/imaging have not yet revealed a source, clarifying the diagnostic uncertainty prompting coronary imaging.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-003", "question": "A 32-year-old woman presents with 3 weeks of migratory polyarthritis, pleuritic chest pain, and low-grade fever. Exam: malar rash sparing nasolabial folds, small bilateral pleural effusions, and mild synovitis of wrists and MCPs. Labs: Hb 10.4 g/dL, platelets 145,000/µL, WBC 3,200/µL, Cr 0.8 mg/dL, urine protein/Cr ratio 0.2, AST/ALT mildly elevated. ESR 75 mm/h, CRP 2.1 mg/dL. ANA 1:640 homogeneous, anti-dsDNA high, low C3/C4. Anti-phospholipid antibodies are negative on two occasions 12 weeks apart. Echocardiogram shows a small pericardial effusion without tamponade. She has a confirmed positive pregnancy test at 6 weeks gestation. Which of the following is the most appropriate initial treatment strategy?", "options": ["Start high-dose prednisone plus mycophenolate mofetil", "Start hydroxychloroquine and low-moderate dose prednisone", "Start methotrexate and high-dose NSAIDs", "Defer immunosuppression and treat with low-dose aspirin alone", "Start belimumab and discontinue hydroxychloroquine once controlled"], "answer": "B", "answer_index": 1, "explanation": "This is new-onset SLE with non-organ-threatening disease in early pregnancy; hydroxychloroquine is recommended in all pregnant SLE patients and improves maternal and fetal outcomes. Low-moderate dose prednisone addresses serositis and arthritis with acceptable fetal safety. Mycophenolate and methotrexate are teratogenic, aspirin alone is inadequate for active disease, and belimumab is not first-line in new, non-severe SLE in pregnancy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 32-year-old pregnant woman (6 weeks) with new-onset SLE: malar rash, migratory polyarthritis, pleuritic chest pain, small pleural and pericardial effusions (serositis), cytopenias, high-titer ANA and anti-dsDNA with low complement, but no renal, CNS, or other organ–threatening involvement. Antiphospholipid antibodies negative; disease is active but non–organ-threatening. Pregnancy requires agents with good maternal–fetal safety.\\nChoice B (hydroxychloroquine + low–moderate dose prednisone) aligns with guidelines: HCQ recommended for all pregnant SLE patients and steroids at lowest effective dose for serositis/arthritis. \\nChoice A: mycophenolate is teratogenic and reserved for organ-threatening disease. \\nChoice C: methotrexate is contraindicated in pregnancy; high-dose NSAIDs are avoided in early pregnancy and inadequate alone. \\nChoice D: aspirin alone does not treat active SLE and APS labs are negative. \\nChoice E: belimumab is not first-line for new, mild–moderate SLE and HCQ should not be discontinued.\\nMain issues: None significant; scenario and management choice are consistent with current standards.\\nMinimal fix: Clarify glucocorticoid dose range in the option (e.g., “prednisone ≤0.5 mg/kg/day”) to emphasize pregnancy-appropriate dosing, though not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 32-year-old pregnant woman (6 weeks) with new-onset SLE: malar rash, migratory polyarthritis, pleuritic chest pain, small pleural and pericardial effusions (serositis), cytopenias, high-titer ANA and anti-dsDNA with low complement, but no renal, CNS, or other organ–threatening involvement. Antiphospholipid antibodies negative; disease is active but non–organ-threatening. Pregnancy requires agents with good maternal–fetal safety.\nChoice B (hydroxychloroquine + low–moderate dose prednisone) aligns with guidelines: HCQ recommended for all pregnant SLE patients and steroids at lowest effective dose for serositis/arthritis. \nChoice A: mycophenolate is teratogenic and reserved for organ-threatening disease. \nChoice C: methotrexate is contraindicated in pregnancy; high-dose NSAIDs are avoided in early pregnancy and inadequate alone. \nChoice D: aspirin alone does not treat active SLE and APS labs are negative. \nChoice E: belimumab is not first-line for new, mild–moderate SLE and HCQ should not be discontinued.\nMain issues: None significant; scenario and management choice are consistent with current standards.\nMinimal fix: Clarify glucocorticoid dose range in the option (e.g., “prednisone ≤0.5 mg/kg/day”) to emphasize pregnancy-appropriate dosing, though not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-004", "question": "A 61-year-old man with obesity and hypertension presents with exertional dyspnea and occasional chest tightness. Resting ECG is normal. Transthoracic echocardiogram shows EF 60%, mild concentric LVH, and no valvular disease. He undergoes a standard exercise treadmill test using Bruce protocol. At stage 3, he develops 2-mm horizontal ST depression in leads V4-V6 and II, III, aVF with peak HR 142/min (89% of predicted). He has no chest pain and BP rises appropriately. Nuclear perfusion imaging done concurrently shows normal perfusion and normal LV function at rest and stress. Coronary CT angiography reveals a short left main with separate LAD and LCx ostia, no atherosclerotic plaque, and a myocardial bridge in the mid-LAD with 80% systolic compression but preserved diastolic lumen. Which is the best next step in management?", "options": ["Start high-dose beta-blocker therapy and avoid further ischemic workup", "Refer for percutaneous coronary intervention with stenting of the bridged segment", "Order invasive coronary angiography with pressure-wire assessment during dobutamine stress", "Schedule surgical myotomy of the myocardial bridge", "Reassure the patient and no further follow-up is required"], "answer": "C", "answer_index": 2, "explanation": "The discordance between ischemic ST changes and normal perfusion imaging in the setting of a significant myocardial bridge raises concern for dynamic flow limitation, especially at higher heart rates not reached on standard testing. Invasive angiography with physiologic assessment (FFR/iFR or diastolic FFR during inotropic stress) clarifies hemodynamic significance and guides need for intensified medical or surgical therapy. Empiric high-dose beta-blockers or surgery without confirming significance is premature, and PCI in bridged segments has high complication rates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Patient has exertional dyspnea/chest tightness; exercise treadmill shows multilead 2-mm horizontal ST depression but no symptoms and appropriate BP; nuclear perfusion imaging and LV function are normal; coronary CTA shows no atherosclerotic disease but a mid-LAD myocardial bridge with 80% systolic compression and preserved diastolic lumen. This creates discordant noninvasive data (positive ECG, negative perfusion) in the context of an anatomic anomaly that can cause dynamic ischemia under higher inotropic stress than achieved (only 89% of predicted HR).\\nOption C (invasive coronary angiography with physiologic assessment during inotropic stress) is appropriate to determine the hemodynamic significance of the bridge before escalating to high-dose beta-blockers or surgery, and to avoid PCI in a bridged segment, which is known to have complications. \\nOptions A and E are unsafe/insufficient given persistent symptoms plus abnormal stress ECG; B (PCI) is generally discouraged in myocardial bridging; D (surgical myotomy) is reserved for proven hemodynamically significant, refractory cases—premature without physiologic confirmation. No major medical inaccuracies identified.\\nMinimal fix: Explicitly state that symptoms persist despite optimal basic medical therapy to further justify invasive physiologic assessment.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Patient has exertional dyspnea/chest tightness; exercise treadmill shows multilead 2-mm horizontal ST depression but no symptoms and appropriate BP; nuclear perfusion imaging and LV function are normal; coronary CTA shows no atherosclerotic disease but a mid-LAD myocardial bridge with 80% systolic compression and preserved diastolic lumen. This creates discordant noninvasive data (positive ECG, negative perfusion) in the context of an anatomic anomaly that can cause dynamic ischemia under higher inotropic stress than achieved (only 89% of predicted HR).\nOption C (invasive coronary angiography with physiologic assessment during inotropic stress) is appropriate to determine the hemodynamic significance of the bridge before escalating to high-dose beta-blockers or surgery, and to avoid PCI in a bridged segment, which is known to have complications. \nOptions A and E are unsafe/insufficient given persistent symptoms plus abnormal stress ECG; B (PCI) is generally discouraged in myocardial bridging; D (surgical myotomy) is reserved for proven hemodynamically significant, refractory cases—premature without physiologic confirmation. No major medical inaccuracies identified.\nMinimal fix: Explicitly state that symptoms persist despite optimal basic medical therapy to further justify invasive physiologic assessment.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-005", "question": "A 28-year-old woman at 36 weeks gestation presents to the ED with severe headache, visual blurring, and nausea. BP is 188/118 mm Hg, HR 96/min. She is agitated and reports seeing flashing lights. Reflexes are brisk with 3+ patellar reflexes and 1-2 beats of clonus. Labs: platelets 102,000/µL, AST 105 U/L, ALT 98 U/L, Cr 1.2 mg/dL, urine protein/Cr ratio 1.0. Shortly after arrival, she has a generalized tonic-clonic seizure lasting 90 seconds, then becomes postictal. Oxygen saturation is 95% on 2 L nasal cannula. Fetal heart monitoring is reassuring. She has already received a 4-g IV loading dose of magnesium sulfate en route. Which is the most appropriate immediate next step after stabilizing airway and breathing?", "options": ["Administer an additional 2-g IV magnesium bolus and start IV labetalol", "Start continuous propofol infusion and emergent head CT before antihypertensives", "Give IV levetiracetam, discontinue magnesium, and proceed to emergent cesarean delivery", "Start nicardipine infusion targeting BP <120/80 mm Hg and delay delivery for 48 hours", "Administer IV diazepam and begin oral labetalol once she awakens"], "answer": "A", "answer_index": 0, "explanation": "She has eclampsia with severe features; magnesium is first-line for seizure control and recurrence prevention, and a repeat bolus is appropriate after a breakthrough seizure on therapy. Rapid parenteral antihypertensive (e.g., IV labetalol) is needed to control severe BP, with expeditious delivery once stabilized. Propofol, levetiracetam alone, aggressive BP lowering to normal, or delaying delivery are not appropriate initial strategies.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 36 weeks gestation, new-onset severe hypertension (188/118 mm Hg), proteinuria, thrombocytopenia, elevated AST/ALT, hyperreflexia with clonus, and a generalized tonic-clonic seizure after receiving a 4-g IV magnesium load. These findings are classic for eclampsia on magnesium prophylaxis with a breakthrough seizure. After ABCs, management priorities are: ensure adequate magnesium level (repeat bolus allowed for recurrent/breakthrough seizure) and treat severe-range BP with rapid-acting parenteral antihypertensive (IV labetalol, hydralazine, or nifedipine), while planning prompt delivery. Choice A appropriately adds a supplemental 2-g magnesium bolus and initiates IV labetalol.\\nOther options: B inappropriately prioritizes propofol and head CT over urgent BP control and magnesium optimization. C wrongly stops magnesium and substitutes levetiracetam, and commits to emergent cesarean despite reassuring fetal status. D over-lowers BP to normal range and delays delivery, both contrary to standard care. E uses diazepam (not first-line) and only oral labetalol.\\nMain medical accuracy issue(s): None significant; targets and drug choices match current obstetric standards.\\nMinimal fix: Clarify in stem that magnesium infusion is already running to emphasize this is a breakthrough seizure on standard dosing, further justifying the repeat bolus choice.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 36 weeks gestation, new-onset severe hypertension (188/118 mm Hg), proteinuria, thrombocytopenia, elevated AST/ALT, hyperreflexia with clonus, and a generalized tonic-clonic seizure after receiving a 4-g IV magnesium load. These findings are classic for eclampsia on magnesium prophylaxis with a breakthrough seizure. After ABCs, management priorities are: ensure adequate magnesium level (repeat bolus allowed for recurrent/breakthrough seizure) and treat severe-range BP with rapid-acting parenteral antihypertensive (IV labetalol, hydralazine, or nifedipine), while planning prompt delivery. Choice A appropriately adds a supplemental 2-g magnesium bolus and initiates IV labetalol.\nOther options: B inappropriately prioritizes propofol and head CT over urgent BP control and magnesium optimization. C wrongly stops magnesium and substitutes levetiracetam, and commits to emergent cesarean despite reassuring fetal status. D over-lowers BP to normal range and delays delivery, both contrary to standard care. E uses diazepam (not first-line) and only oral labetalol.\nMain medical accuracy issue(s): None significant; targets and drug choices match current obstetric standards.\nMinimal fix: Clarify in stem that magnesium infusion is already running to emphasize this is a breakthrough seizure on standard dosing, further justifying the repeat bolus choice.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-006", "question": "A 9-year-old boy presents with 3 months of diffuse musculoskeletal pain, morning stiffness lasting 30-45 minutes, and profound fatigue. He was previously athletic but now avoids activity due to pain. Exam shows generalized tenderness over muscles and entheses, mild limitation of lumbar flexion, and no clear joint effusions. No rash, fevers, or weight loss. Labs: CBC, ESR, CRP, CK, aldolase, and TSH are normal. ANA 1:80 speckled, RF negative, HLA-B27 negative. XR of sacroiliac joints and spine are normal. He has fragmented sleep, difficulty focusing at school, and abdominal pain without alarm features. Which strategy is most appropriate to establish the correct diagnosis and direct management?", "options": ["Order whole-body MRI to evaluate for enthesitis-related arthritis or occult malignancy", "Diagnose juvenile fibromyalgia and implement a graded exercise and CBT program", "Perform lumbar puncture and brain MRI to evaluate for CNS vasculitis", "Start a 3-month trial of NSAIDs and low-dose prednisone for suspected JIA", "Order EMG and nerve conduction studies to exclude small fiber neuropathy"], "answer": "B", "answer_index": 1, "explanation": "Chronic widespread pain, normal inflammatory and muscle markers, non-restorative sleep, cognitive complaints, and functional GI symptoms are characteristic of juvenile fibromyalgia. Early diagnosis with emphasis on graded aerobic/strength exercise and cognitive behavioral therapy is key. Whole-body MRI, CNS workup, empiric steroids, or EMG are unnecessary and potentially harmful in this presentation.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 9-year-old with 3 months of diffuse musculoskeletal pain, morning stiffness limited to 30–45 minutes, profound fatigue, nonrestorative/fragmented sleep, cognitive difficulties, functional abdominal pain, normal CBC/ESR/CRP/CK/aldolase/TSH, minimal objective musculoskeletal findings (tenderness without effusion), low-titer nonspecific ANA, and normal spine/SI radiographs. These findings strongly support juvenile fibromyalgia/central sensitization rather than inflammatory, malignant, neuromuscular, or neuropathic disease.\\nOption B is best: It directly names juvenile fibromyalgia and outlines first-line management (graded aerobic/strength exercise and CBT), which aligns with current pediatric rheumatology standards once serious disease is excluded by normal exam and labs.\\nOther options: A (whole-body MRI) is unnecessary given reassuring labs and lack of focal findings; C (LP/brain MRI) is unsupported—no neuro deficits or systemic vasculitis clues; D (NSAIDs + prednisone for “suspected JIA”) is inappropriate without objective arthritis or inflammation; E (EMG/NCS) would not diagnose small fiber neuropathy and pain pattern is not neuropathic.\\nMain medical issues: None substantive; workup exclusion and management are accurate.\\nMinimal fix: Explicitly state duration of symptoms as ≥3 months of widespread pain to mirror formal fibromyalgia criteria terminology.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 9-year-old with 3 months of diffuse musculoskeletal pain, morning stiffness limited to 30–45 minutes, profound fatigue, nonrestorative/fragmented sleep, cognitive difficulties, functional abdominal pain, normal CBC/ESR/CRP/CK/aldolase/TSH, minimal objective musculoskeletal findings (tenderness without effusion), low-titer nonspecific ANA, and normal spine/SI radiographs. These findings strongly support juvenile fibromyalgia/central sensitization rather than inflammatory, malignant, neuromuscular, or neuropathic disease.\nOption B is best: It directly names juvenile fibromyalgia and outlines first-line management (graded aerobic/strength exercise and CBT), which aligns with current pediatric rheumatology standards once serious disease is excluded by normal exam and labs.\nOther options: A (whole-body MRI) is unnecessary given reassuring labs and lack of focal findings; C (LP/brain MRI) is unsupported—no neuro deficits or systemic vasculitis clues; D (NSAIDs + prednisone for “suspected JIA”) is inappropriate without objective arthritis or inflammation; E (EMG/NCS) would not diagnose small fiber neuropathy and pain pattern is not neuropathic.\nMain medical issues: None substantive; workup exclusion and management are accurate.\nMinimal fix: Explicitly state duration of symptoms as ≥3 months of widespread pain to mirror formal fibromyalgia criteria terminology.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-007", "question": "A 63-year-old woman with a 15-year history of seropositive rheumatoid arthritis (RA) presents with progressive dyspnea and dry cough over 4 months. Medications: methotrexate 20 mg weekly (for 10 years), low-dose prednisone 5 mg daily, and adalimumab for 3 years. She has no fevers or weight loss. Exam reveals bibasilar fine inspiratory crackles and mild digital clubbing. PFTs show FVC 62% predicted, FEV1/FVC 0.85, and DLCO 40% predicted. HRCT of the chest shows subpleural reticulation, traction bronchiectasis, and honeycombing predominantly in the bases, consistent with a usual interstitial pneumonia (UIP) pattern. There are no ground-glass opacities. Which is the most appropriate modification of her RA and lung disease management?", "options": ["Discontinue methotrexate permanently and increase adalimumab dose", "Continue current RA regimen and add nintedanib", "Stop adalimumab and switch to rituximab while continuing methotrexate", "Stop methotrexate and adalimumab, and start high-dose prednisone plus azathioprine", "Add mycophenolate mofetil to current regimen for treatment of ILD"], "answer": "B", "answer_index": 1, "explanation": "This is RA-associated ILD with a UIP pattern, which behaves like idiopathic pulmonary fibrosis and typically does not respond to high-dose immunosuppression. Nintedanib slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and can be added while stable articular disease is controlled. Routine methotrexate cessation is not clearly beneficial here, and switching biologics or adding mycophenolate is more appropriate for inflammatory (e.g., NSIP) patterns rather than established fibrotic UIP.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Long-standing seropositive RA; progressive exertional dyspnea and dry cough; exam with basilar crackles and clubbing; PFTs with restrictive pattern (low FVC, preserved FEV1/FVC) and markedly reduced DLCO; HRCT showing a basal, subpleural fibrotic UIP pattern with honeycombing and no ground-glass opacities. This strongly supports RA-associated fibrotic ILD with a UIP phenotype, which clinically behaves like IPF and is poorly responsive to escalation of immunosuppression.\\nOption B (continue RA regimen, add nintedanib) aligns with current evidence that antifibrotic therapy (e.g., nintedanib) slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and that routine methotrexate cessation is not clearly indicated in established RA-ILD without clear MTX toxicity. Other options are weaker: A lacks rationale to stop MTX and inappropriately increases TNF inhibitor; C switches to rituximab and continues MTX without clear benefit in fibrotic UIP; D uses high-dose steroids/azathioprine, which are ineffective/harmful in UIP; E adds mycophenolate, more appropriate for inflammatory NSIP-type disease rather than established UIP fibrosis. No major medical inaccuracies identified.\\nMinimal fix: State explicitly that her articular RA is currently well controlled to justify not changing RA immunotherapy while adding antifibrotic treatment.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Long-standing seropositive RA; progressive exertional dyspnea and dry cough; exam with basilar crackles and clubbing; PFTs with restrictive pattern (low FVC, preserved FEV1/FVC) and markedly reduced DLCO; HRCT showing a basal, subpleural fibrotic UIP pattern with honeycombing and no ground-glass opacities. This strongly supports RA-associated fibrotic ILD with a UIP phenotype, which clinically behaves like IPF and is poorly responsive to escalation of immunosuppression.\nOption B (continue RA regimen, add nintedanib) aligns with current evidence that antifibrotic therapy (e.g., nintedanib) slows FVC decline in progressive fibrosing ILDs, including RA-ILD, and that routine methotrexate cessation is not clearly indicated in established RA-ILD without clear MTX toxicity. Other options are weaker: A lacks rationale to stop MTX and inappropriately increases TNF inhibitor; C switches to rituximab and continues MTX without clear benefit in fibrotic UIP; D uses high-dose steroids/azathioprine, which are ineffective/harmful in UIP; E adds mycophenolate, more appropriate for inflammatory NSIP-type disease rather than established UIP fibrosis. No major medical inaccuracies identified.\nMinimal fix: State explicitly that her articular RA is currently well controlled to justify not changing RA immunotherapy while adding antifibrotic treatment.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-008", "question": "A 45-year-old man with poorly controlled type 2 diabetes (A1c 10.8%), BMI 36 kg/m², and mild nonproliferative diabetic retinopathy presents for follow-up. Medications: metformin 1000 mg BID and basal insulin glargine 35 units nightly. He had an episode of acute pancreatitis 3 years ago attributed to severe hypertriglyceridemia (TG 1,800 mg/dL); since then, triglycerides have been controlled around 250-300 mg/dL on fenofibrate. He drinks no alcohol. eGFR is 65 mL/min/1.73 m², AST/ALT are mildly elevated (1.5× ULN), and ultrasound shows fatty liver without biliary disease. He is interested in newer injectable therapies for weight loss and glucose control. Which glucose-lowering agent is most appropriate to add now?", "options": ["Liraglutide", "Semaglutide", "Dulaglutide", "Tirzepatide", "Empagliflozin"], "answer": "E", "answer_index": 4, "explanation": "Given prior pancreatitis, any incretin-based therapy (GLP-1 receptor agonists and dual GIP/GLP-1 agonists like tirzepatide) carries a theoretical risk of recurrence, and product labels recommend caution or avoidance. An SGLT2 inhibitor such as empagliflozin improves glycemic control, promotes modest weight loss, and provides CV/renal benefits without known pancreatitis signal. His eGFR is adequate, making empagliflozin the safest choice among the listed options.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Prior acute pancreatitis clearly attributed to hypertriglyceridemia; currently controlled TG but history remains; patient wants newer injectable options; very poorly controlled T2DM with obesity; on metformin and basal insulin; eGFR 65; mild transaminitis and fatty liver; no alcohol use. Among options, four are incretin-based injectables (liraglutide, semaglutide, dulaglutide, tirzepatide) vs one SGLT2 inhibitor (empagliflozin).\\nThe most likely teaching point is that a history of pancreatitis is a precaution for GLP‑1 RAs and related agents, especially when alternatives exist. Empagliflozin adds glycemic control, modest weight loss, and CV/renal benefits with no established pancreatitis signal and is safe at this eGFR, making it the best choice despite not being injectable.\\nAlternatives: A–D all are GLP‑1 or GIP/GLP‑1 injectables, which product labels advise avoiding/caution in prior pancreatitis; choosing among them is not supported. No logical contradictions or missing critical data; the stem gives enough to exclude incretin therapy on safety grounds.\\nMain medical issue: the risk is “theoretical/precaution” rather than proven, but boards usually treat prior pancreatitis as a relative contraindication.\\nMinimal fix: Explicitly state “you wish to avoid agents with a pancreatitis warning” to reinforce the intended logic.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Prior acute pancreatitis clearly attributed to hypertriglyceridemia; currently controlled TG but history remains; patient wants newer injectable options; very poorly controlled T2DM with obesity; on metformin and basal insulin; eGFR 65; mild transaminitis and fatty liver; no alcohol use. Among options, four are incretin-based injectables (liraglutide, semaglutide, dulaglutide, tirzepatide) vs one SGLT2 inhibitor (empagliflozin).\nThe most likely teaching point is that a history of pancreatitis is a precaution for GLP‑1 RAs and related agents, especially when alternatives exist. Empagliflozin adds glycemic control, modest weight loss, and CV/renal benefits with no established pancreatitis signal and is safe at this eGFR, making it the best choice despite not being injectable.\nAlternatives: A–D all are GLP‑1 or GIP/GLP‑1 injectables, which product labels advise avoiding/caution in prior pancreatitis; choosing among them is not supported. No logical contradictions or missing critical data; the stem gives enough to exclude incretin therapy on safety grounds.\nMain medical issue: the risk is “theoretical/precaution” rather than proven, but boards usually treat prior pancreatitis as a relative contraindication.\nMinimal fix: Explicitly state “you wish to avoid agents with a pancreatitis warning” to reinforce the intended logic.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-009", "question": "A 27-year-old woman is brought to the ED after collapsing during a 10-km race. Bystanders report sudden loss of consciousness without seizure activity; CPR was started immediately, and an AED delivered one shock for ventricular fibrillation with ROSC. She is now awake and oriented. No drugs or supplements; family history notable for an uncle who died suddenly at 32 while swimming, presumed drowning. Vitals: HR 78/min, BP 112/68 mm Hg, normal exam. Labs and echocardiogram are normal. Baseline ECG shows QTc 460 ms, normal QRS, and normal ST-T waves. During recovery from an exercise treadmill test, she develops polymorphic VT that terminates spontaneously; QTc in recovery is 510 ms with late-appearing T waves in V2-V4. Which is the most appropriate next step in management?", "options": ["Implant an ICD and start high-dose beta-blocker therapy", "Start nadolol and schedule left cardiac sympathetic denervation", "Start flecainide in addition to beta-blocker therapy", "Begin verapamil and restrict participation to low-intensity sports", "Perform genetic testing for catecholaminergic polymorphic VT before any therapy"], "answer": "A", "answer_index": 0, "explanation": "This presentation is consistent with congenital long QT syndrome (likely LQT1 or LQT2) with exercise-associated VF arrest and marked QT prolongation in recovery. Survivors of cardiac arrest from LQTS require ICD plus beta-blocker therapy. LCSD or flecainide may be adjuncts in selected cases but not first-line over ICD after arrest. Verapamil is ineffective, and genetic testing should not delay life-saving therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: Young woman with out-of-hospital VF arrest during exertion, normal echo, baseline borderline QTc (460 ms) but clear QTc prolongation in recovery (510 ms) with abnormal T waves, exercise-triggered polymorphic VT, and family history of presumed drowning in a young relative. This constellation is classic for congenital long QT syndrome with high-risk features (cardiac arrest survivor, exertional trigger, abnormal recovery QT behavior).\\n\\nGuideline-consistent management for a survivor of LQTS-related VF arrest is ICD implantation plus nonselective beta-blocker therapy; this makes option A the single best answer. Nadolol and LCSD (B) are appropriate therapies but LCSD is adjunctive when beta-blocker ± ICD is inadequate, not a substitute for ICD after arrest. Flecainide (C) is an adjunct in some LQTS genotypes but not first-line over ICD in a cardiac arrest survivor. Verapamil (D) is not standard therapy for LQTS and sports restriction alone is inadequate. Genetic testing (E) is indicated but must not delay definitive, life-saving treatment.\\n\\nMain medical accuracy issues: None significant; teaching point aligns with contemporary consensus.\\n\\nMinimal fix: Clarify “high-dose nonselective beta-blocker (eg, nadolol)” in option A to emphasize preferred agent class for LQTS.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: Young woman with out-of-hospital VF arrest during exertion, normal echo, baseline borderline QTc (460 ms) but clear QTc prolongation in recovery (510 ms) with abnormal T waves, exercise-triggered polymorphic VT, and family history of presumed drowning in a young relative. This constellation is classic for congenital long QT syndrome with high-risk features (cardiac arrest survivor, exertional trigger, abnormal recovery QT behavior).\n\nGuideline-consistent management for a survivor of LQTS-related VF arrest is ICD implantation plus nonselective beta-blocker therapy; this makes option A the single best answer. Nadolol and LCSD (B) are appropriate therapies but LCSD is adjunctive when beta-blocker ± ICD is inadequate, not a substitute for ICD after arrest. Flecainide (C) is an adjunct in some LQTS genotypes but not first-line over ICD in a cardiac arrest survivor. Verapamil (D) is not standard therapy for LQTS and sports restriction alone is inadequate. Genetic testing (E) is indicated but must not delay definitive, life-saving treatment.\n\nMain medical accuracy issues: None significant; teaching point aligns with contemporary consensus.\n\nMinimal fix: Clarify “high-dose nonselective beta-blocker (eg, nadolol)” in option A to emphasize preferred agent class for LQTS.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed127-010", "question": "A 7-year-old boy with sickle cell disease (HbSS) presents with acute onset of severe left hip pain and inability to bear weight. He had a pain crisis 2 weeks ago treated with IV opioids and hydration. Temperature is 38.3°C, HR 120/min, BP 96/58 mm Hg. Hip exam reveals extreme pain with any passive motion, especially internal rotation, and the leg is slightly flexed and externally rotated. WBC 18,000/µL, CRP 14 mg/dL, ESR 86 mm/h. Plain radiograph is unremarkable. MRI of the pelvis obtained within 6 hours of symptom onset shows bone marrow edema of the femoral head and neck with a moderate hip joint effusion, but no definite abscess or cortical destruction. Which is the most appropriate next step?", "options": ["Treat as vaso-occlusive crisis with IV opioids and observe for 24-48 hours", "Start broad-spectrum IV antibiotics and schedule urgent surgical hip drainage", "Obtain radionuclide bone scan to differentiate infarction from osteomyelitis", "Repeat pelvic MRI with contrast in 72 hours before deciding on surgery", "Start IV antibiotics and aspirate the hip joint under ultrasound guidance"], "answer": "E", "answer_index": 4, "explanation": "In children with sickle cell disease, distinguishing osteomyelitis/septic arthritis from bone infarction is challenging; fever, high inflammatory markers, inability to bear weight, and effusion demand prompt evaluation. Joint aspiration with culture, ideally under ultrasound guidance, plus empiric IV antibiotics is the appropriate next step to diagnose or exclude septic arthritis early. Delaying for observation or repeat imaging risks joint destruction; bone scan is nonspecific in this setting, and immediate surgical drainage without diagnostic aspiration may be premature without frank clinical sepsis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 7-year-old with HbSS; acute severe hip pain with inability to bear weight; low-grade fever, tachycardia, elevated WBC, CRP, and ESR; severe pain with passive motion/internal rotation; hip held flexed and externally rotated; MRI within hours showing marrow edema of femoral head/neck and moderate effusion, no abscess or cortical destruction. These findings strongly raise concern for early septic arthritis/osteomyelitis versus infarction, but the presence of effusion plus systemic inflammation and inability to bear weight mandate urgent diagnostic aspiration and empiric IV antibiotics.\\nOption E is appropriate: diagnostic (aspiration with culture under US guidance) and therapeutic (start IV antibiotics) without delaying care. A is unsafe under-treating possible septic arthritis. B (immediate surgical drainage) is more appropriate for definite septic arthritis or frank sepsis, not just suspected; aspiration first is standard. C (bone scan) adds delay and limited specificity in SCD. D (wait 72 hours and repeat MRI) risks joint destruction by delaying diagnosis and treatment.\\nMedical accuracy issues: None significant; approach aligns with pediatric and sickle cell standards.\\nMinimal fix: Specify empiric coverage (eg, vancomycin plus third-generation cephalosporin) in the explanation for added clarity, not required for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 7-year-old with HbSS; acute severe hip pain with inability to bear weight; low-grade fever, tachycardia, elevated WBC, CRP, and ESR; severe pain with passive motion/internal rotation; hip held flexed and externally rotated; MRI within hours showing marrow edema of femoral head/neck and moderate effusion, no abscess or cortical destruction. These findings strongly raise concern for early septic arthritis/osteomyelitis versus infarction, but the presence of effusion plus systemic inflammation and inability to bear weight mandate urgent diagnostic aspiration and empiric IV antibiotics.\nOption E is appropriate: diagnostic (aspiration with culture under US guidance) and therapeutic (start IV antibiotics) without delaying care. A is unsafe under-treating possible septic arthritis. B (immediate surgical drainage) is more appropriate for definite septic arthritis or frank sepsis, not just suspected; aspiration first is standard. C (bone scan) adds delay and limited specificity in SCD. D (wait 72 hours and repeat MRI) risks joint destruction by delaying diagnosis and treatment.\nMedical accuracy issues: None significant; approach aligns with pediatric and sickle cell standards.\nMinimal fix: Specify empiric coverage (eg, vancomycin plus third-generation cephalosporin) in the explanation for added clarity, not required for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]